NCT03253744 is a phase 1 trial with the primary objective to identify the maximum tolerated dose (MTD) of focal, salvage stereotactic body radiation therapy (SBRT) for patients with radiorecurrent prostate cancer (i.e., local recurrence after prior external beam radiotherapy). The trial followed a classic 3+3 design with the plan to evaluate 3 increasing dose levels (DLs) of 40 Gy (DL1), 42.5 Gy (DL2), and 45 Gy (DL3) each delivered in 5 fractions. The target volume was defined by both multiparametric magnetic resonance imaging (mpMRI) and PSMA-based PET/CT with the 18F-DCFPyL radiotracer.

Biographies:

Krishnan R. Patel, MD, Assistant Research Physician, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD